A Clinical Management Incident That Shook Trust

In the clinical trial information system managed by the Ministry of Food and Drug Safety (MFDS), lax document access controls left clinical trial-related materials visible from outside, and it was also confirmed that the personal information of 1,195 people was leaked amid criticism that 2,672 files could be downloaded. This showed that not only the content of clinical trials but also administrative data linked to participant and staff information had not been sufficiently separated and protected, deepening doubts about the regulatory authority’s basic security capabilities.

This issue is connected not so much to a single incident at the MFDS as to a broader trend in which security investment and operational practices across the public research and regulatory sectors have failed to keep pace with the speed of real-world threats. In fact, even at national research institutions, only 395 out of 14,989 servers had antivirus software installed, revealing that the public sector handling bio and R&D information is structurally vulnerable to digital risks.

Fake Data and a Reexamination of Review Procedures

The Genencell case went beyond a simple deviation by an individual company and raised anew the question of how effectively the authenticity of submitted materials can be verified during reviews of clinical trial plans, and how far requests for supplementation should be allowed to go. Behind the MFDS’s statement that it had commissioned a policy study was the judgment that trust would be difficult to restore through existing review methods alone, given that the submission of false data and approval lobbying developed into an actual criminal case and a related figure received a four-year prison sentence in the appellate court and was taken into custody in court.

In line with this, a recently released clinical trial status investigation also confirmed major flaws in the management system for materials used in approval applications. A case in which "critical" and "major" findings were issued in the areas of quality assurance and quality control of clinical trial data shows that document review at the screening stage alone is not enough to fully guarantee the reliability of the entire process of data generation and management.

The Rise of Previously Unseen Management Gaps

As a significant portion of domestic clinical trials are conducted within multinational structures, blind spots in oversight are also growing. Although around 400 cases, or about 60% of approved trials each year, are global clinical trials, the government has not even been able to systematically compile the scale of specimens sent overseas or the status of the analyzing institutions, allowing gaps in data quality and jurisdictional responsibility to accumulate.

These gaps are not limited to pharmaceutical clinical trials, but are repeated in adjacent regulatory areas such as materials for cosmetic procedures derived from the human body and education accreditation. There have been criticisms that, as with human tissue-based cosmetic injections, the system for evaluating safety and effectiveness in advance is not sufficient. In addition, a court has found in another evaluation system that objectivity and fairness were seriously undermined during the evaluation process, making it clear that the authority of such systems cannot be maintained through formal procedures alone.

Stronger Verification, Growing Industry Burdens

From now on, the direction of regulation is likely to shift away from simply supporting market entry and toward more closely scrutinizing data integrity, quality control, and post-approval responsibility. This is necessary for protecting patients and restoring market trust, but at the same time it could significantly increase the cost burden on companies and institutions that must now handle clinical design, documentation, quality assurance, and information security.

Ultimately, the key change shown by these reports is that clinical and approval systems can no longer be sustained with a document-submission-centered approach. Review authorities must substantially improve their verification capabilities, and companies have entered a phase in which not only research results themselves but also the records and operational systems that prove them must become part of their competitiveness.